|Other Names||Wee1-like protein kinase, WEE1hu, Wee1A kinase, WEE1|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP3285a was selected from the 46~60 |
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Acts as a negative regulator of entry into mitosis (G2 to M transition) by protecting the nucleus from cytoplasmically activated cyclin B1-complexed CDK1 before the onset of mitosis by mediating phosphorylation of CDK1 on 'Tyr-15'. Specifically phosphorylates and inactivates cyclin B1-complexed CDK1 reaching a maximum during G2 phase and a minimum as cells enter M phase. Phosphorylation of cyclin B1-CDK1 occurs exclusively on 'Tyr-15' and phosphorylation of monomeric CDK1 does not occur. Its activity increases during S and G2 phases and decreases at M phase when it is hyperphosphorylated. A correlated decrease in protein level occurs at M/G1 phase, probably due to its degradation.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes a nuclear protein, which is a tyrosine kinase belonging to the Ser/Thr family of protein kinases. This protein catalyzes the inhibitory tyrosine phosphorylation of CDC2/cyclin B kinase, and appears to coordinate the transition between DNA replication and mitosis by protecting the nucleus from cytoplasmically activated CDC2 kinase.
Dai, X., et al., J. Invest. Dermatol. 122(6):1356-1364 (2004).Watanabe, N., et al., Proc. Natl. Acad. Sci. U.S.A. 101(13):4419-4424 (2004).Yoshida, T., et al., Ann. Oncol. 15(2):252-256 (2004).Kawasaki, H., et al., Oncogene 22(44):6839-6844 (2003).Yuan, H., et al., J. Virol. 77(3):2063-2070 (2003).
If you have any additional inquiries please email technical services at email@example.com.